Recent evidence implicates CGRP in the pathophysiology of a subset of NDPH cases with migraine-like characteristics [5], suggesting that CGRP-targeted therapies may offer both therapeutic benefit and diagnostic insight. The gene discussed is CALCA; the disease is migraine disorder.